Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy

Ruan, Weimin; Jiao, Mingzhu; Xu, Sen; Xie, Xuan; An, Yang; Guo, Haixing; Ran, Qian; Shi, Bingyang; Zheng, Meng

doi:10.1016/j.jconrel.2022.09.046

Cited by 25 publications

(22 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nano RNP endowed high circulating ability, improved tumor accumulation, and efficient disruption of STAT3 and RUNX1, which resulted in the satisfying growth suppression of the heterogeneous tumor. In addition, Zheng et al fabricated a brain‐targeted Cas9/gRNA RNP based nanoparticles by decorating an angiopep‐2 on guanidinium and fluorine functionalized polymer (poly(ethylene glycol)‐block‐poly(N‐(3‐methacrylamidopropyl) guanidinium) (Ang‐PEG‐b‐PGu)/poly(ethylene glycol)‐block‐poly[(N‐(3‐methacrylamidopropyl) guanidinium‐co‐2,2,3,3‐tetrafluoropropyl methacrylate] (PEG‐b‐P(GuF)); Figure 7e; Ruan et al, 2022). The guanidinium and fluorine parts of polymeric nanoparticles interacted with Cas9/gRNA RNP to stabilize it and facilitate endosomal escape.…”

Section: Delivery Strategies Of Crispr/cas Systems For Cancer Therapymentioning

confidence: 99%

“…Kang and colleagues reported a pH-sensitive nanoRNP constructed by polylysine (PLys) mixed with Cas9 RNPs as the core and then bridged with poly (ethylene glycol) via 2,5-dihydro-2,5-dioxofuran-3-acetic acid (CA) as the shell (Figure 7d; Liu, Cai, et al, 2019). Nano RNP endowed (3-methacrylamidopropyl) guanidinium-co-2,2,3,3-tetrafluoropropyl methacrylate] (PEG-b-P(GuF)); Figure 7e; Ruan et al, 2022). The guanidinium and fluorine parts of polymeric nanoparticles interacted with Cas9/ gRNA RNP to stabilize it and facilitate endosomal escape.…”

Section: Other Polymeric Materialsmentioning

confidence: 99%

Section: Delivery Strategies Of Crispr/cas Systems For Cancer Therapymentioning

confidence: 99%

See 2 more Smart Citations

CRISPR/Cas gene editing and delivery systems for cancer therapy

Li,

Zhou,

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

CRISPR/Cas systems stand out because of simplicity, efficiency, and other superiorities, thus becoming attractive and brilliant gene‐editing tools in biomedical field including cancer therapy. CRISPR/Cas systems bring promises for cancer therapy through manipulating and engineering on tumor cells or immune cells. However, there have been concerns about how to overcome the numerous physiological barriers and deliver CRISPR components to target cells efficiently and accurately. In this review, we introduced the mechanisms of CRISPR/Cas systems, summarized the current delivery strategies of CRISPR/Cas systems by physical methods, viral vectors, and nonviral vectors, and presented the current application of CRISPR/Cas systems in cancer clinical treatment. Furthermore, we discussed prospects related to delivery approaches of CRISPR/Cas systems.This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Section: Delivery Strategies Of Crispr/cas Systems For Cancer Therapymentioning

confidence: 99%

Section: Other Polymeric Materialsmentioning

confidence: 99%

See 1 more Smart Citation

CRISPR/Cas gene editing and delivery systems for cancer therapy

Li,

Zhou,

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Zheng et al synthesized an angiopep-2 modified, guanidinium and fluorine decorated polymer to encapsulate RNP. 248 Angiopep-2 peptide on the nanoparticles enabled the brain targeting and blood-brain barrier (BBB) penetrating for the treatment of glioblastoma multiforme (GBM). The guanidinium and fluorine components improved the interaction with RNP and its stability in the blood circulation.…”

Section: Polymer-based Nanotechnologymentioning

confidence: 99%

Nanotechnology‐based CRISPR/Cas9 delivery system for genome editing in cancer treatment

Zhou,

Li,

et al. 2024

MedComm – Biomaterials and Applications

View full text Add to dashboard Cite

The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (CRISPR/Cas9) systems initiate a revolution in genome editing, which have a significant potential for treating cancer. A significant amount of research has been conducted regarding genetic modification using CRISPR/Cas9 systems, and 33 clinical trials using ex vivo or in vivo CRISPR/Cas9 gene editing techniques have been carried out to treat cancer. Despite its potential advantages, the main obstacle to convert CRISPR/Cas9 technology into clinical genome editing applications is the safe and efficient transport of genetic material owing to various extra‐ and intracellular biological hurdles. We outline the characteristics of three forms of CRISPR/Cas9 cargos, plasmids, mRNA/sgRNA, and ribonucleoprotein (RNP) complexes in this review. The recent in vivo nanotechnology‐based delivery techniques for these three categories to treat cancer are then reviewed. In the end, we outline the prerequisites for effective and secure in vivo CRISPR/Cas9 delivery in clinical contexts and discuss challenges with current nanocarriers. This review offers a thorough overview of the CRISPR/Cas9 nano‐delivery system for the treatment of cancer, serving as a resource for the design and building of CRISPR/Cas9 delivery systems and offering fresh perspectives on the treatment of tumors.

show abstract

“…When exposed to alternating current magnetic fields, ZnCoFe NCs could be used in BBTB modulation and synergistic magnetic hyperthermia for glioblastoma treatment. Ruan et al [66] designed an innovative polymeric brain delivery system to treat human orthotopic glioblastoma by ribonucleoprotein, modified with angiopep-2 and loading Cas9/gRNA. The results showed that polymeric nanoparticles with great BBB penetration and tumor accumulation had long blood circulation time and significantly improved medium survival time of nude mice in vitro and in vivo models of glioblastoma.…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Nanoparticles Mediated the Diagnosis and Therapy of Glioblastoma: Bypass or Cross the Blood–Brain Barrier

Song

Qian

2023

Small

View full text Add to dashboard Cite

Glioblastoma is one of the most aggressive central nervous system malignancies with high morbidity and mortality. Current clinical approaches, including surgical resection, radiotherapy, and chemotherapy, are limited by the difficulty of targeting brain lesions accurately, leading to disease recurrence and fatal outcomes. The lack of effective treatments has prompted researchers to continuously explore novel therapeutic strategies. In recent years, nanomedicine has made remarkable progress and expanded its application in brain drug delivery, providing a new treatment for brain tumors. Against this background, this article reviews the application and progress of nanomedicine delivery systems in brain tumors. In this paper, the mechanism of nanomaterials crossing the blood‐brain barrier is summarized. Furthermore, the specific application of nanotechnology in glioblastoma is discussed in depth.

show abstract

Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy

Cited by 25 publications

References 43 publications

CRISPR/Cas gene editing and delivery systems for cancer therapy

CRISPR/Cas gene editing and delivery systems for cancer therapy

Nanotechnology‐based CRISPR/Cas9 delivery system for genome editing in cancer treatment

Nanoparticles Mediated the Diagnosis and Therapy of Glioblastoma: Bypass or Cross the Blood–Brain Barrier

Contact Info

Product

Resources

About